Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor

Chemical Biology and Drug Design

Volumn 72, Issue 5, 2008, Pages 350-359

  Li, Zeng ^a   Han, Jin ^a   Chen, Hai Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

3D QSAR; Diaryltriazine Analog (DATA) Inhibitor; HIV 1 reverse transcriptase; Molecular dynamics simulation; Non nucleoside inhibitors

Indexed keywords

DIARYLTRIAZINE DERIVATIVE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIMULATION; THREE DIMENSIONAL IMAGING;

ANTI-HIV AGENTS; BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZINES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 54249115423     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00713.x     Document Type: Article

References (37)

1. Jonckheere H., Anne J., De Clercq E. (2000) The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev 20 : 129 154.
2. Hopkins A.L., Ren J., Esnouf R.M., Willcox B.E., Jones E.Y., Ross C., Miyasaka T., Walker R.T., Tanaka H., Stammers D.K., Stuart D.I. (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 39 : 1589 1600.
3. Pereira C.F., Paridaen J.T. (2004) Anti-HIV drug development - an overview. Curr Pharm Des 10 : 4005 4037.
4. Wynn G.H., Zapor M.J., Smith B.H., Wortmann G., Oesterheld J.R., Armstrong S.C., Cozza K.L. (2004) Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics 45 : 262 270.
5. Zapor M.J., Cozza K.L., Wynn G.H., Wortmann G.W., Armstrong S.C. (2004) Antiretrovirals, part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 45 : 524 535.
6. Boojamra C.G., Mackman R.L., Markevitch D.Y., Prasad V., Ray A.S., Douglas J., Grant D., Kim C.U., Cihlar T. (2008) Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor. Bioorg Med Chem Lett 18 : 1120 1123.
7. Wainberg M.A., Cahn P., Bethell R.C., Sawyer J., Cox S. (2007) Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. Antiviral Chem Chemother 18 : 61 70.
8. Uckun F.M., Tibbles H.E., Venkatachalam T.K., Erbeck D. (2007) In vivo pharmacokinetics, metabolism, toxicity, and anti-HIV activity of N'-[2-(2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a potent non-nucleoside inhibitor of HIV reverse transcriptase. Arzneim Forsch 57 : 483 496.
9. Xiong Y.Z., Chen F.E., Balzarini J., De Clercq E., Pannecouque C. (2007) Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity. Eur J Med Chem 43 : 1230 1236.
10. Rawal R.K., Tripathi R.K., Katti S.B., Pannecouque C., De Clercq E. (2007) Synthesis and biological evaluation of 2,3-diaryl substituted-1,3- thiazolidin-4-ones as anti-HIV agents. Med Chem 3 : 355 363.
11. Wu J., Liu X., Cheng X., Cao Y., Wang D., Li Z., Xu W., Pannecouque C., Witvrouw M., De Clercq E. (2007) Synthesis of novel derivatives of 4-amino-3-(2-furyl)-5-mercapto-1,2,4-triazole as potential HIV-1 NNRTIs. Molecules 12 : 2003 2016.
12. Chen H.F., Fan B.T., Zhao C.Y., Xie L., Zhao C.H., Zhou T., Lee K.H., Allaway G. (2005) Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogs. J Comput Aided Mol Des 19 : 243 258.
13. Gulick R.M. (2003) New antiretroviral drugs. Clin Microbiol Infect 9 : 186 193.
14. De Clercq E. (2002) New anti-HIV agents and targets. Med Res Rev 22 : 531 565.
15. Wang J., Morin P., Wang W., Kollman P.A. (2001) Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 123 : 5221 5230.
16. Tantillo C., Ding J., Jacobo-Molina A., Nanni R.G., Boyer P.L., Hughes S.H., Pauwels R., Andries K., Janssen P.A., Arnold E. (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 243 : 369 387.
17. Ludovici D.W., Kavash R.W., Kukla M.J., Ho C.Y., Ye H., De Corte B.L., Andries K. et al. (2001) Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Bioorg Med Chem Lett 11 : 2229 2234.
18. Das K., Clark A.D. Jr., Lewi P.J., Heeres J., De Jonge M.R., Koymans L.M., Vinkers H.M. et al. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47 : 2550 2560.
19. Kireev D.B., Chretien J.R., Grierson D.S., Monneret C. (1997) A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition. J Med Chem 40 : 4257 4264.
20. Cramer R.D., Patterson D.E., Bunce J.D. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on Binding of steroids to carrier proteins. J Am Chem Soc 110 : 5959 5967.
21. Klebe G., Abraham U., Mietzner T. (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37 : 4130 4146.
22. Chen H.F., Yao X.J., Li Q., Yuan S.G., Panaye A., Doucet J.P., Fan B.T. (2003) Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking. SAR QSAR Environ Res 14 : 455 474.
23. Clark M., Cramer I.R.D., Van Opdenbosh N. (1989) The Tripos force field. J Comput Chem 10 : 982 1012.
24. Cho S.J., Tropsha A. (1995) Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. J Med Chem 38 : 1060 1066.
25. Clark M., Cramer R.D. (1993) The probability of chance correlation using partial least squares (PLS). Quant Struct Act Relat 12 : 137 145.
26. Bohm M., Stürzebecher J., Klebe G. (1999) Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 42 : 458 477.
27. Kollman P.A., Dixon R.W., Cornell W.D., Chipot C., Pohorille A. (1997) The development / application of "minimalist" organic / biochemical molecular mechanic force field using a combination of ab initio calculations and experimental data. In : van Gunsteren W.F., Weiner P.K., Wilkinson A.J., editors. Computer Simulations of Biological Systems, vol. 3. Dordrecht, The Netherlands : ESCOM p. 83 96.
28. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79 : 926 935.
29. Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. (2004) Development and testing of a general amber force field. J Comput Chem 25 : 1157.
30. Rychaert J.P., Ciccotti G., Berendsen H.J.C. (1977) Numerical integration of Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23 : 327 341.
31. Darden TYD., Pedersen L. (1993) Particle mesh ewald: an n·log(N) method for ewald sums in large systems. J Chem Phys 98 : 10089 10092.
32. Wallace A.C., Laskowski R.A., Thornton J.M. (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8 : 127 134.
33. Rodriguez-Barrios F., Balzarini J., Gago F. (2005) The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. J Am Chem Soc 127 : 7570 7578.
34. Barreca M.L., Rao A., De Luca L., Iraci N., Monforte A.M., Maga G., De Clercq E., Pannecouque C., Balzarini J., Chimirri A. (2007) Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem Lett 17 : 1956 1960.
35. Medina-Franco J.L., Rodriguez-Morales S., Juarez-Gordiano C., Hernandez-Campos A., Castillo R. (2004) Docking-based CoMFA and CoMSIA studies of non-nucleoside reverse transcriptase inhibitors of the pyridinone derivative type. J Comput Aided Mol Des 18 : 345 360.
36. Ragno R., Mai A., Sbardella G., Artico M., Massa S., Musiu C., Mura M., Marturana F., Cadeddu A., La Colla P. (2004) Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl] -3,4-dihydro-5-alkylpyrimidin- 4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J Med Chem 47 : 928 934.
37. Das K., Lewi P.J., Hughes S.H., Arnold E. (2005) Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 88 : 209 231.